Mehmet TOSUN, Fatih ÖZCAN, Erdinç SERİN, Güler BUĞDAYCI

Obez kadınlarda paraoksonaz1 aktivitesinin lipit metabolizması ile ilişkisi

Objective: The aim of this study was to identify the effects of serum lipids, apolipoprotein (apo) A-I, apo B and paraoxonase/arylesterase (PON1) activity on obesity in women.Methods: The study was conducted on 90 subjects categorized into three groups; there were 30 women in each group with an age range of 18-48 years. Group 1 had 30 abdominal obese patients, group 2 had 30 gynoid obeses and group 3 included 30 healthy control subjects.Results: There was a statistically significant difference between the triglyceride, high-density lipoprotein cholesterol (HDL-C), apo B, direct low-density lipoprotein cholesterol (D-LDL-C), high sensitive-CRP (hsCRP), homeostasis model insulin resistance (HOMA-IR) levels of group 1 and 2 (p=0.001, p

The relationship of paraoxonase 1 activity with lipid metabolism in obese women

PDF

___

Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 2007; 132: 2087-102.
Kota SK, Meher LK, Kota SK, Jammula S, Krishna SVS. Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia. Indian J Endocrinol and Metab 2013; 17: 402-12.
Faraj M, Lavoie ME, Messier L, Bastard JP, Prudhomme D. Reduction in serum apoB is associated with reduced inflammation and insulin resistance in post-menopausal women: A MONET study. Atherosclerosis 2010; 211: 682-8.
Tabur S, Torun AN, Sabuncu T, Turan MN, Celik H, Ocak AR et al. Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation. Eur Journal Endocrinol2010; 162: 535-41.
Furlong CE, Suzuki SM, Stevens RC. Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact 2010; 187: 355-61.
Dragonov DI, La Du NB. Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedebergs. Arch Pharmocol 2004; 369: 78-88.
Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological diffuculties in measurement. Crit Rev Clin Lab Sci 2009; 46:83-106.
Chudek J, Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep 2006; 58: 81-8.
National Institutes of Health, National Heart, Lung, and Blood Institute: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-in evidence report. Obes Res 1998; 6: 51-209.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher BF, Turner RC. Homeostasis model assesment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabeteologia 1985; 28: 412-9.
Salgado JV, Neves FA, Bastos MG, Franca AK, Brito DJ, Santas EM. Monitoring renal function: measured and estimated glomerular filtration rates - a review. Braz J Med Biol Res 2010; 43: 528-36.
Monteiro R and Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators of Inflammation 2010; doi: 10.1155/2010 289645.
Seres I, Bajnok L, Harangi M, Sztanek F, Koncsos P, Paragh G. Alteration of PON1 activity in adult and childhood obesity and its relation to adipokine levels. Adv Exp Med Biol 2010; 660: 129-42.
Tabak O, Gelişgen R, Çicekci H, Şenateş E, Erdenen F, Müderrisoğlu C et al. Circulating levels of adiponectin, orexin-A, ghrelin and the antioxidant paraoxonase-1 in metabolic sydrome. Minerva Med 2012; 103: 323-9.
Rainwater DL, VandeBerg JL, Mahaney MC. Effects of diet on genetic regulation of lipoprotein metabolism in baboons. Atherosclerosis 2010; 213: 499-504.
Hong-Liang L, De-Pei L, Chihj-Chuan L. Paraoxonase gene polymorphisms, oxidative stress and diseases. J Mol Med 2003; 81: 766-79.
Browne RW, Koury ST, Marion S, Wilding G, Muti P, Trevisan M. Accuracy and Biological Variation of Human Serum Praoxonase I Activity and Polymorphism (Q192R) by Kinetic Enzyme Assay. Clin Chem 2007; 53: 310-7.
Veiga L, Silva-Nunes JA, Melão A, Olivera A, Duarte L, Brito M. Q192R polymorphism of the paraoxonase-1 gene as a risk factor for obesity in Portuguese women. Eur J Endocrinol 2011; 164: 213-8.
Ferretti G, Bacchetti T, Masciangelo S, Biocchiega V. HDL-paraoxonase and membrane lipid peroxidaiton: a comparison between healthy and obese subjects. Obesity 2010; 18: 1079-84.
Ayer JG, Harmer JA, David C, S Steinbeck K, Seale JP, Celermajer DS. Severe obesity is associated with impaired with arterial smooth muscle function in young adults. Obesity 2011; 19: 54-60.
Agrawal M, Spencer HJ, Faas FH. Method of LDL cholesterol measurement influences classification of LDL cholesterol treatment goals: clinical research study. J Investig Med 2010; 58: 945-9.
Otokozawa S, Ai M, Asztalos BF. Direct assessment of plazma low density lipoprotein and high density lipoprotein cholesterol levels and coronary heart disease: results from the Framingham Offspring Study. Atherosclerosis 2010; 213: 251-65.
Revenga-Frauca J, Gonzales-Gil EM, Bueno-Lozano G, De Miguel-Etayo P, Velasco-Martinez P, Rey Lopez JP. Abdominal fat and metabolic risk in obese children and adolescents. J Physiol Biochem 2009; 65: 415-20.
Souza FAC, Dias R, Fernandes CE, Pimentel F, Dias D. Menstrual irregularity: a possible clinical marker of metabolic dysfunction in women with class III obesity. Gynecol Endocrinol 2010; 26: 768-72.
Ghandehari H, Le V, Kamal-Bahl S, Bassin SL, Wong ND. Abdominal obesity and the spectrum of global cardiometabolic risks in US adults. Int J Obes 2009; 33: 239-48.
Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996; 45: 633-8.